What is it about?
Intention is to foster the initial benefit of biologic agents in ulcerative colitis.
Photo by Fabio Ballasina on Unsplash
Why is it important?
Should we combine biologic agents and immunomodulators in ulcerative colitis ? And which one to consider or not to favor to increase the therapeutic efficacy of the first one ? Is it of benefit for each biologic agents ?
Read the Original
This page is a summary of: Combination of vedolizumab and immunomodulators in ulcerative colitis, Journal of Gastroenterology and Hepatology, September 2021, Wiley, DOI: 10.1111/jgh.15686.
You can read the full text:
The following have contributed to this page